Devonian Health Group Inc. DVHGF
Set alert
5.88 USD 0.00 0.00%
At close · Oct 30
4.94 Day range 4.95
4.27 52-week range 10.65
- YTD
- +37.59%
- 1 year
- +37.59%
- Open
- 4.95
- Prev close
- 5.88
- Mkt cap
- 16.34M
- Vol
- 200
- Avg vol
- 68
- EPS
- -1.54
- P/E
- 0.00
More statistics
- Low
- 4.94
- High
- 4.95
2Y chart
Events in this range
- Jan 22, 2026Split: 1 for 60
Signals (26)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| MACD: Buy Signal | Jul 14, 2026 | 3 months ago |
| SMA: Bearish | Jun 23, 2026 | 4 months ago |
| RSI: Oversold | Jun 23, 2026 | 4 months ago |
| MACD: Sell Signal | Mar 13, 2026 | 7 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| RSI: Overbought | Feb 23, 2026 | 8 months ago |
| MACD: Buy Signal | Oct 9, 2025 | 1 year ago |
| SMA: Bearish | Sep 19, 2025 | 1 year ago |
| RSI: Oversold | Sep 19, 2025 | 1 year ago |
| MACD: Sell Signal | May 23, 2025 | 1 year ago |
| MACD: Buy Signal | May 6, 2025 | 1 year ago |
| RSI: Overbought | May 6, 2025 | 1 year ago |
| SMA: Bearish | May 2, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 14, 2025 | 1 year ago |
| SMA: Bullish | Feb 21, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 21, 2025 | 1 year ago |
| RSI: Overbought | Feb 21, 2025 | 1 year ago |
| SMA: Bearish | Jan 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 31, 2025 | 1 year ago |
| RSI: Oversold | Jan 31, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 30, 2025 | 1 year ago |
| RSI: Overbought | Jan 30, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 23, 2024 | 1 year ago |
| RSI: Overbought | Dec 5, 2024 | 1 year ago |
News
- Devonian Health Group Receives Health Canada Authorization to Evaluate Novel Thykamine™ Formulation for Prevention of Radiation-Induced Skin Injury in Breast Cancer Patients
- Devonian Health Group Provides Update on its Planned NYSE American Listing
- Devonian Health Group Provides Update on its Planned NYSE American Listing
- Devonian Health Group Inc. Anticipates to Commence Trading on the NYSE American
- Devonian Health Group Strengthens Thykamine™ Manufacturing Platform with Validated Chemical-Composition Fingerprinting and Biological Potency Assay
- Devonian Health Group Anticipates to Commence Trading on the NYSE American
- Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
- Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
- Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years
- Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026
Your note
Sign in to keep a note on DVHGF — it syncs with the Stock Master app.